{"id":"NCT00817063","sponsor":"Stiefel, a GSK Company","briefTitle":"Efficacy and Safety of a Retinoid in the Treatment of Severe Chronic Hand Eczema","officialTitle":"Efficacy and Safety of Alitretinoin in the Treatment of Severe Chronic Hand Eczema Refractory to Topical Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-01-08","primaryCompletion":"2012-04-26","completion":"2012-04-26","firstPosted":"2009-01-06","resultsPosted":"2017-11-09","lastUpdate":"2020-04-27"},"enrollment":599,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Eczema"],"interventions":[{"type":"DRUG","name":"alitretinoin","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Alitretinoin","type":"EXPERIMENTAL"},{"label":"Placebo","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to investigate the safety and efficacy of alitretinoin in the treatment of severe chronic hand eczema that does not respond to treatment with potent topical steroids.","primaryOutcome":{"measure":"Number of Participants Who Responded as Per Physician's Global Assessment (PGA) at Week 24","timeFrame":"Week 24 (end-of-treatment)","effectByArm":[{"arm":"Alitretinoin 30 mg","deltaMin":58,"sd":null},{"arm":"Placebo","deltaMin":14,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":6},"locations":{"siteCount":70,"countries":["United States"]},"refs":{"pmids":["17868211","15611422","18294310","25607554"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":296},"commonTop":["Headache","Upper respiratory tract infection","Nausea","Flushing"]}}